Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology conference.

10 Jun 2010

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

9 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.

7 Jun 2010

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma, according to results disclosed in an oral presentation today at the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).

7 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

NICE denies availability of Sorafenib liver cancer drug on NHS

Sorafenib (brand name Nexavar) will not be made available on the NHS for people with advanced hepatocellular carcinoma, the most common form of primary liver cancer.

28 May 2010

Researchers report key cellular pathway in deadly brain cancer malignant glioma

Researchers at the University of Massachusetts Medical School report in the journal Nature Medicine on a cellular pathway in the deadly brain cancer malignant glioma, a pathway essential to the cancer's ability to grow - and a potential target for therapy that would stop the cancer's ability to thrive.

26 May 2010

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Sorafenib News and Research

Combination of SIR-Spheres and Sorafenib confers survival benefit for patients with inoperable HCC

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Addition of sorafenib to chemotherapy regimen not effective against advanced melanoma: Study

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

NICE denies availability of Sorafenib liver cancer drug on NHS

Researchers report key cellular pathway in deadly brain cancer malignant glioma

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Targeted therapy based on molecular signatures for treating lung cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News